Alpha-fetoprotein, vaginal bleeding and pregnancy risk

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Reproductive Health

Background:

• Maternal serum alpha-fetoprotein (MSAFP) screening is a key component of prenatal care.
• Vaginal bleeding during pregnancy is a recognized risk factor for adverse outcomes.
• The combined predictive value of MSAFP levels and vaginal bleeding has not been previously analyzed.

Purpose of the Study:

• To investigate the interrelation between maternal serum alpha-fetoprotein (MSAFP) levels and vaginal bleeding.
• To assess their combined impact as risk factors for fetal death and low birthweight in singleton pregnancies.

Main Methods:

• A cohort study of 6829 singleton pregnancies without fetal malformations in the second trimester.
• Analysis of maternal serum alpha-fetoprotein (MSAFP) levels (in multiples of the median, MoM) and reported vaginal bleeding.
• Calculation of relative risks for fetal death and low birthweight based on combined risk factor categories.

Main Results:

• MSAFP levels and vaginal bleeding were largely independent predictors of fetal death.
• The highest relative risk for fetal death (12.6) was observed with elevated MSAFP (≥2.0 MoM) and vaginal bleeding.
• Risks for low birthweight were also elevated with combined factors, with mean birthweights decreasing as risk increased.

Conclusions:

• Maternal serum alpha-fetoprotein (MSAFP) and vaginal bleeding act as independent risk factors during pregnancy.
• Their combination, especially elevated MSAFP with bleeding, significantly elevates the risk of fetal death and low birthweight.
• This combined assessment provides a more comprehensive risk evaluation for adverse pregnancy outcomes.